查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2086140

無針給藥裝置市場：2026-2032年全球市場預測（按產品類型、藥物類型、給藥途徑、應用、最終用戶和分銷管道分類）

Needle Free Drug Delivery Device Market by Product Type, Drug Type, Administration Route, Application, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，無針給藥裝置市場將成長至 314.1 億美元，複合年成長率為 13.31%。

主要市場統計數據
基準年 2025 130.9億美元
預計年份：2026年 147.6億美元
預測年份 2032 314.1億美元
複合年成長率 (%) 13.31%

無針給藥裝置市場簡介

隨著人們對更安全、以患者為中心的傳統注射替代方案的需求日益成長，無針給藥裝置的市場在醫療保健領域正在擴大。無針注射器、微針平台、經皮吸收系統和連網型穿戴式裝置給藥裝置旨在無需使用傳統皮下注射針即可輸送生物製藥、疫苗、胰島素、荷爾蒙和鎮痛藥。

無針給藥方式的變革性變化

醫療保健格局正從以醫院注射為主的模式轉向分散式照護轉變，患者期望在家中就能便捷、可靠且無痛地服用藥物。兼具易用性和精準劑量的重複給藥系統的需求日益成長，其促進因素包括糖尿病、自體免疫疾病、偏頭痛、不孕症治療、荷爾蒙療法和長期生物製藥療法等。

人工智慧對無針設備的累積影響

人工智慧 (AI) 正透過設計最佳化、製造品質提升、互聯藥物依從性支援以及上市後監測等方式，開始影響無針給藥裝置的價值鏈。借助 AI 驅動的模擬技術，工程師可以在創建物理原型之前評估噴嘴形狀、注射壓力、微針陣列性能、穿戴式裝置機制以及皮膚相互作用等變數。

關於無針給藥的關鍵區域見解

亞太地區市場正經歷擴張，這主要得益於中國、印度、日本、韓國和澳洲等國家龐大的慢性疾病患者，以及其先進的疫苗基礎設施、生產能力和數位化醫療的普及。中國和印度充分利用其在糖尿病治療、免疫接種計劃和經濟高效的醫療器械部署方面的規模優勢，而日本、韓國和澳洲則專注於高品質的醫療器械，並致力於解決人口老齡化、家庭醫療保健以及符合監管規定的創新路徑。

針對東協、海灣合作理事會、歐盟、金磚國家、七國集團和北約的關鍵群體特定見解

在東協市場，公共衛生計畫、擴大中產階級醫療保健服務覆蓋範圍以及區域製造業舉措正在推動便捷式藥物輸送技術的應用，使其日益重要。市場需求與疫苗接種、糖尿病管理和基層醫療密切相關，但市場准入需要嚴格的定價策略、高品質的經銷商、多語言患者教育以及臨床醫生培訓。

各國對無針頭給藥的洞察

美國在創新、臨床研究、醫療設備法規核准流程以及生物製藥在慢性病和專科疾病治療中的應用方面處於主導地位。加拿大透過其省級醫療保健系統，優先考慮安全性、品質和可及性；墨西哥則憑藉其作為製造地的地理位置接近性、醫療設備生產能力以及對慢性病治療日益成長的需求，佔據市場主導地位。巴西擁有龐大的人口基數、完善的公共免疫接種計劃以及不斷擴大的私人醫療保健服務，是拉丁美洲最具影響力的市場。

為行業領導者提供的實用建議

產業領導者應優先考慮藥物與醫療設備的早期相容性，尤其對於生物製藥、胜肽類藥物、疫苗、胰島素、荷爾蒙和高黏度製劑。原因包括劑量準確性、生物利用度、使用者偏好、注射部位耐受性、防滲漏性以及在不同膚質、年齡層和護理環境下的表現。

調查方法

本執行摘要基於系統性的二手研究方法，利用公開且檢驗的資訊來源，包括全球衛生組織、監管指南、臨床文獻、標準化機構、醫療安全研究途徑和公共衛生數據。分析重點在於已證實的行業促進因素，例如慢性病管理、疫苗接種、預防銳器傷、居家醫療、生物製藥的給藥以及醫療設備-藥品組合的要求。

結論

無針給藥裝置正從利基替代方案轉變為更安全、更便利、更擴充性的治療給藥策略平台。最大的商業機會正湧現於慢性病流行、生物製藥療法擴展、疫苗接種方案、醫護人員安全和居家照護等因素的交會點。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 無針給藥裝置市場：依產品類型分類

  • 噴射注射器
    • 燃氣驅動
    • 彈簧型
  • 微陣列貼片
    • 溶解的微陣列
    • 中空微陣列
    • 固體微陣列

第8章 無針給藥裝置市場：依藥物類型分類

  • 胰島素
    • 基礎胰島素
      • 中效胰島素
      • 長效胰島素
    • Bolus胰島素
      • 超速效胰島素
      • 速效胰島素
  • 疫苗
    • 2019冠狀病毒病疫苗
      • 藥效疫苗
      • 病毒載體疫苗
    • 流感疫苗
      • H5N1禽流感
      • 季節性流感

第9章 無針給藥裝置市場：依給藥途徑分類

  • 皮內給藥
  • 肌肉內部
  • 皮下

第10章 無針給藥裝置市場：依應用領域分類

  • 皮膚科
  • 糖尿病管理
  • 疫苗接種
  • 疼痛管理

第11章 無針給藥裝置市場：依最終用戶分類

  • 門診手術中心
  • 診所
  • 居家醫療
  • 醫院

第12章 無針給藥裝置市場：依分銷管道分類

  • 離線
  • 線上

第13章 無針給藥裝置市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第14章 無針給藥裝置市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 無針給藥裝置市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • 3M Company
  • Antares Pharma, Inc.
  • Becton, Dickinson and Company（BD）
  • Bioject Medical Technologies Inc.
  • Crossject SA
  • Endo International plc
  • Gerresheimer AG
  • Haselmeier GmbH
  • Injex Pharma AG
  • Inovio Pharmaceuticals, Inc.
  • Medical International Technology, Inc.
  • National Medical Products Inc.
  • Nemera Development SA
  • NuGen Medical Devices Inc.
  • PenJet Corporation
  • PharmaJet, Inc.
  • Portal Instruments, Inc.
  • Schott AG
  • SHL Medical AG
  • Stevanato Group SpA
  • Valeritas Holdings, Inc.
  • West Pharmaceutical Services, Inc.
  • Ypsomed Holding AG
  • Zogenix, Inc.
Product Code: MRR-036C5CF3B48C

The Needle Free Drug Delivery Device Market is projected to grow by USD 31.41 billion at a CAGR of 13.31% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 13.09 billion
Estimated Year [2026] USD 14.76 billion
Forecast Year [2032] USD 31.41 billion
CAGR (%) 13.31%

Needle-Free Drug Delivery Device Market Introduction

The needle-free drug delivery device market is advancing as healthcare systems pursue safer, more patient-centered alternatives to conventional injections. Needle-free injectors, microneedle platforms, transdermal systems, and connected wearable delivery devices are designed to administer biologics, vaccines, insulin, hormones, and pain therapies without a traditional hypodermic needle.

Demand is supported by measurable clinical and operational needs. The World Health Organization has reported that billions of injections are administered globally each year, while the U.S. CDC has estimated hundreds of thousands of sharps injuries annually among hospital-based healthcare personnel. These facts keep needlestick prevention, infection-control efficiency, healthcare worker safety, and medication adherence at the center of procurement decisions.

For manufacturers, providers, and investors, the opportunity is no longer limited to needle aversion. It now includes chronic disease self-management, mass immunization readiness, biologic drug lifecycle management, reduced sharps waste, dose accuracy, and digitally enabled dose tracking across home care and clinical settings.

Transformative Shifts in Needle-Free Delivery

The landscape is shifting from hospital-administered injections toward decentralized care, where patients expect convenient, reliable, and less painful drug delivery at home. Diabetes, autoimmune disorders, migraine, fertility care, hormone therapy, and long-term biologic treatment are increasing the need for repeat-administration systems that combine usability with dose accuracy.

Regulatory expectations are also reshaping product design. Needle-free drug delivery devices must demonstrate biocompatibility, mechanical reliability, human-factors validation, sterility assurance, and, for combination products, performance with the drug formulation itself. This is especially important for biologics and high-viscosity formulations, where delivery force, fill volume, and tissue penetration depth affect clinical performance.

Sustainability and health-worker safety are becoming differentiators. Needle-free systems can reduce reliance on exposed sharps and may lower injury-related workflow burden when properly implemented. Competitive advantage is increasingly tied to evidence generation, device-drug compatibility, connected monitoring, patient training, and scalable manufacturing quality.

Cumulative Impact of AI on Needle-Free Devices

Artificial intelligence is beginning to influence the needle-free drug delivery device value chain through design optimization, manufacturing quality, connected adherence support, and post-market surveillance. AI-enabled simulation can help engineers evaluate nozzle geometry, injection pressure, microneedle array performance, wearable device mechanics, and skin-interaction variables before physical prototyping.

In production, machine vision and predictive analytics can strengthen defect detection for micro-scale components, springs, cartridges, seals, reservoirs, and wearable device assemblies. These applications are particularly relevant where small dimensional variations can affect dose delivery, leakage risk, or patient comfort.

In patient use, AI can support dose reminders, adherence risk scoring, injection-site rotation guidance, and anomaly detection from connected devices. However, AI adoption must be governed by cybersecurity, explainability, data privacy, clinical validation, and regulatory controls, particularly when software influences clinical decision-making or dosing behavior.

Key Regional Insights for Needle-Free Drug Delivery

Asia-Pacific is expanding as China, India, Japan, South Korea, and Australia combine large chronic disease populations with growing vaccine infrastructure, manufacturing capability, and digital health adoption. China and India offer scale for diabetes care, immunization programs, and cost-sensitive device deployment, while Japan, South Korea, and Australia emphasize high-quality devices, aging-population care, home-based treatment, and regulated innovation pathways.

North America remains a leading commercialization region due to advanced reimbursement systems, high biologics use, diabetes prevalence, strong regulated pathways for device-drug combination products, and established home healthcare adoption. The United States is especially important for connected needle-free injectors, wearable injectors, autoinjector alternatives, and pediatric or needle-phobia applications, while Canada supports adoption through quality-focused public healthcare systems and patient safety priorities.

Europe benefits from mature medical device oversight, strong pharmacovigilance systems, and demand for safer occupational healthcare practices, with the EU MDR reinforcing clinical evidence, post-market surveillance, and risk management requirements. Latin America shows opportunity in Brazil and Mexico as access to chronic disease treatment and private healthcare expands. The Middle East is supported by high diabetes burden, health modernization, and premium hospital infrastructure, while Africa presents targeted opportunities in vaccination initiatives, infectious disease programs, and diabetes care, with adoption influenced by affordability, training, procurement models, and supply-chain resilience.

Key Group Insights Across ASEAN, GCC, EU, BRICS, G7, and NATO

ASEAN markets are gaining relevance as public health programs, expanding middle-class healthcare access, and regional manufacturing initiatives support adoption of user-friendly drug delivery technologies. Demand is linked to vaccination delivery, diabetes management, and primary care access, while market entry requires pricing discipline, distributor quality, multilingual patient education, and clinician training.

The GCC is positioned for premium adoption through advanced hospital systems, high diabetes burden, and government investment in health modernization. The European Union offers a structured but demanding environment where MDR compliance, clinical evidence, post-market surveillance, usability engineering, and sustainability considerations are central to product acceptance.

BRICS countries represent major volume potential, led by China, India, and Brazil, but success depends on localization, affordability, domestic regulatory navigation, and partnerships that support training and service availability. G7 markets remain the benchmark for evidence-based commercialization, connected device integration, cybersecurity expectations, and combination product approvals. NATO countries, while not a healthcare trade bloc, include many high-income systems focused on medical preparedness, resilient supply chains, occupational safety, and sharps-safety standards.

Key Country Insights for Needle-Free Drug Delivery

The United States leads in innovation, clinical research activity, regulated device pathways, and use of biologics for chronic and specialty diseases. Canada emphasizes safety, quality, and access through provincial healthcare systems, while Mexico offers manufacturing proximity, medical device production capability, and growing chronic care demand. Brazil is the most influential Latin American market, supported by a large population, public immunization experience, and expanding private healthcare use.

In Europe, the United Kingdom, Germany, France, Italy, and Spain present strong demand for evidence-backed needle-free systems in home care, vaccination, and specialty drug delivery. Germany and France are particularly important for reimbursement scrutiny, clinical validation, and quality requirements, while the United Kingdom supports digital health integration and real-world evidence. Italy and Spain offer adoption potential through aging populations and chronic disease management needs. Russia remains relevant through domestic healthcare demand, although sanctions, procurement constraints, and regulatory complexity can affect market access.

China and India are central to long-term scale because of population size, diabetes prevalence, vaccine capacity, and manufacturing ecosystems. Japan prioritizes quality, aging-population care, and patient-friendly delivery systems suited to home treatment. South Korea combines digital health capability with advanced device manufacturing, while Australia offers a transparent regulatory environment, strong safety standards, and adoption potential for reliable home-based therapies.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize drug-device compatibility early, especially for biologics, peptides, vaccines, insulin, hormones, and high-viscosity formulations. Evidence should include dose accuracy, bioavailability, user preference, injection-site tolerability, leakage performance, and performance across skin types, age groups, and care settings.

Companies should invest in human-factors engineering, connected adherence features, cybersecurity, and manufacturability from the start. Partnerships with pharmaceutical firms, contract manufacturers, diabetes care providers, vaccination programs, payers, and digital health platforms can accelerate commercialization and strengthen real-world evidence generation.

Market access strategies should be region-specific. Premium markets require strong clinical, usability, safety, and health-economic evidence, while emerging markets need cost-effective designs, training materials, local service models, and durable supply chains. Privacy, software validation, and post-market surveillance must be built into connected needle-free delivery platforms.

Research Methodology

This executive summary is based on a structured secondary-research approach using publicly available, verifiable sources, including global health agencies, regulatory guidance, clinical literature, standards bodies, healthcare safety references, and public health data. The analysis emphasizes validated industry drivers such as chronic disease management, vaccination delivery, sharps injury prevention, home healthcare, biologic therapy administration, and device-drug combination requirements.

The methodology triangulates qualitative and quantitative indicators across regions, country healthcare infrastructure, regulatory maturity, disease burden, technology readiness, manufacturing capability, and commercialization feasibility. No unsupported proprietary market-size, market-share, or forecasting claims are used; insights are framed around documented healthcare needs, regulatory realities, and observable technology trends.

Findings are reviewed for consistency with medical device dynamics, including human-factors validation, manufacturing quality, sterility assurance, risk management, cybersecurity, post-market surveillance, and evidence requirements for clinical adoption.

Conclusion

Needle-free drug delivery devices are moving from niche alternatives to strategic platforms for safer, more convenient, and more scalable therapy administration. The strongest opportunities are emerging where chronic disease prevalence, biologic therapy growth, vaccine readiness, healthcare worker safety, and home-based care converge.

AI, connected health, and advanced materials will improve device design, quality control, adherence support, and real-world monitoring, but regulatory rigor and clinical evidence will determine adoption. Organizations that combine patient-centered engineering with robust drug-device validation and region-specific market access strategies will be best positioned to lead.

The market outlook is defined by practical healthcare value: reducing needle-related barriers, supporting safer care delivery, improving treatment adherence, and enabling reliable drug administration outside traditional clinical settings.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Needle Free Drug Delivery Device Market, by Product Type

  • 7.1. Jet Injector
    • 7.1.1. Gas Powered
    • 7.1.2. Spring Based
  • 7.2. Microarray Patch
    • 7.2.1. Dissolvable Microarray
    • 7.2.2. Hollow Microarray
    • 7.2.3. Solid Microarray

8. Needle Free Drug Delivery Device Market, by Drug Type

  • 8.1. Insulin
    • 8.1.1. Basal Insulin
      • 8.1.1.1. Intermediate Acting Insulin
      • 8.1.1.2. Long Acting Insulin
    • 8.1.2. Bolus Insulin
      • 8.1.2.1. Rapid Acting Insulin
      • 8.1.2.2. Short Acting Insulin
  • 8.2. Vaccines
    • 8.2.1. Covid-19 Vaccine
      • 8.2.1.1. Mrna Vaccine
      • 8.2.1.2. Viral Vector Vaccine
    • 8.2.2. Influenza Vaccine
      • 8.2.2.1. H5N1 Influenza
      • 8.2.2.2. Seasonal Influenza

9. Needle Free Drug Delivery Device Market, by Administration Route

  • 9.1. Intradermal
  • 9.2. Intramuscular
  • 9.3. Subcutaneous

10. Needle Free Drug Delivery Device Market, by Application

  • 10.1. Dermatology
  • 10.2. Diabetes Management
  • 10.3. Immunization
  • 10.4. Pain Management

11. Needle Free Drug Delivery Device Market, by End User

  • 11.1. Ambulatory Surgical Centers
  • 11.2. Clinics
  • 11.3. Home Care Settings
  • 11.4. Hospitals

12. Needle Free Drug Delivery Device Market, by Distribution Channel

  • 12.1. Offline
  • 12.2. Online

13. Needle Free Drug Delivery Device Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. North America
  • 13.3. Latin America
  • 13.4. Europe
  • 13.5. Middle East
  • 13.6. Africa

14. Needle Free Drug Delivery Device Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Needle Free Drug Delivery Device Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. 3M Company
  • 17.2. Antares Pharma, Inc.
  • 17.3. Becton, Dickinson and Company (BD)
  • 17.4. Bioject Medical Technologies Inc.
  • 17.5. Crossject SA
  • 17.6. Endo International plc
  • 17.7. Gerresheimer AG
  • 17.8. Haselmeier GmbH
  • 17.9. Injex Pharma AG
  • 17.10. Inovio Pharmaceuticals, Inc.
  • 17.11. Medical International Technology, Inc.
  • 17.12. National Medical Products Inc.
  • 17.13. Nemera Development S.A.
  • 17.14. NuGen Medical Devices Inc.
  • 17.15. PenJet Corporation
  • 17.16. PharmaJet, Inc.
  • 17.17. Portal Instruments, Inc.
  • 17.18. Schott AG
  • 17.19. SHL Medical AG
  • 17.20. Stevanato Group S.p.A.
  • 17.21. Valeritas Holdings, Inc.
  • 17.22. West Pharmaceutical Services, Inc.
  • 17.23. Ypsomed Holding AG
  • 17.24. Zogenix, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY DRUG TYPE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY DRUG TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL JET INJECTOR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL JET INJECTOR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL JET INJECTOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL GAS POWERED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL GAS POWERED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL GAS POWERED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL SPRING BASED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL SPRING BASED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL SPRING BASED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL MICROARRAY PATCH MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL MICROARRAY PATCH MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL MICROARRAY PATCH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL DISSOLVABLE MICROARRAY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL DISSOLVABLE MICROARRAY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL DISSOLVABLE MICROARRAY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL HOLLOW MICROARRAY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL HOLLOW MICROARRAY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL HOLLOW MICROARRAY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL SOLID MICROARRAY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL SOLID MICROARRAY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL SOLID MICROARRAY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL INSULIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL INSULIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL INSULIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BASAL INSULIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BASAL INSULIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BASAL INSULIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL INTERMEDIATE ACTING INSULIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL INTERMEDIATE ACTING INSULIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL INTERMEDIATE ACTING INSULIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL LONG ACTING INSULIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL LONG ACTING INSULIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL LONG ACTING INSULIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BOLUS INSULIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BOLUS INSULIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BOLUS INSULIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL RAPID ACTING INSULIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL RAPID ACTING INSULIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL RAPID ACTING INSULIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL SHORT ACTING INSULIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL SHORT ACTING INSULIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL SHORT ACTING INSULIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL COVID-19 VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL COVID-19 VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL COVID-19 VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL MRNA VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL MRNA VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL MRNA VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL VIRAL VECTOR VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL VIRAL VECTOR VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL VIRAL VECTOR VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL H5N1 INFLUENZA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL H5N1 INFLUENZA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL H5N1 INFLUENZA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL SEASONAL INFLUENZA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL SEASONAL INFLUENZA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL SEASONAL INFLUENZA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL INTRADERMAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL INTRADERMAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL INTRADERMAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL INTRAMUSCULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL INTRAMUSCULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL INTRAMUSCULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL DERMATOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL DERMATOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL DERMATOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL DIABETES MANAGEMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL DIABETES MANAGEMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL DIABETES MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL IMMUNIZATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL IMMUNIZATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL IMMUNIZATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL PAIN MANAGEMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL PAIN MANAGEMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL ONLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL ONLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL ONLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY JET INJECTOR, 2018-2032 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY MICROARRAY PATCH, 2018-2032 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY BASAL INSULIN, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY BOLUS INSULIN, 2018-2032 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY COVID-19 VACCINE, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY INFLUENZA VACCINE, 2018-2032 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY JET INJECTOR, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY MICROARRAY PATCH, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 132. NORTH AMERICA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY BASAL INSULIN, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY BOLUS INSULIN, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY COVID-19 VACCINE, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY INFLUENZA VACCINE, 2018-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 138. NORTH AMERICA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 142. LATIN AMERICA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY JET INJECTOR, 2018-2032 (USD MILLION)
  • TABLE 144. LATIN AMERICA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY MICROARRAY PATCH, 2018-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY BASAL INSULIN, 2018-2032 (USD MILLION)
  • TABLE 148. LATIN AMERICA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY BOLUS INSULIN, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 150. LATIN AMERICA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY COVID-19 VACCINE, 2018-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY INFLUENZA VACCINE, 2018-2032 (USD MILLION)
  • TABLE 152. LATIN AMERICA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 154. LATIN AMERICA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY JET INJECTOR, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY MICROARRAY PATCH, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY BASAL INSULIN, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY BOLUS INSULIN, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY COVID-19 VACCINE, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY INFLUENZA VACCINE, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 172. MIDDLE EAST NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. MIDDLE EAST NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY JET INJECTOR, 2018-2032 (USD MILLION)
  • TABLE 174. MIDDLE EAST NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY MICROARRAY PATCH, 2018-2032 (USD MILLION)
  • TABLE 175. MIDDLE EAST NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. MIDDLE EAST NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY BASAL INSULIN, 2018-2032 (USD MILLION)
  • TABLE 178. MIDDLE EAST NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY BOLUS INSULIN, 2018-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 180. MIDDLE EAST NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY COVID-19 VACCINE, 2018-2032 (USD MILLION)
  • TABLE 181. MIDDLE EAST NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY INFLUENZA VACCINE, 2018-2032 (USD MILLION)
  • TABLE 182. MIDDLE EAST NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 184. MIDDLE EAST NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 186. AFRICA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 187. AFRICA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. AFRICA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY JET INJECTOR, 2018-2032 (USD MILLION)
  • TABLE 189. AFRICA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY MICROARRAY PATCH, 2018-2032 (USD MILLION)
  • TABLE 190. AFRICA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. AFRICA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 192. AFRICA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY BASAL INSULIN, 2018-2032 (USD MILLION)
  • TABLE 193. AFRICA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY BOLUS INSULIN, 2018-2032 (USD MILLION)
  • TABLE 194. AFRICA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 195. AFRICA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY COVID-19 VACCINE, 2018-2032 (USD MILLION)
  • TABLE 196. AFRICA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY INFLUENZA VACCINE, 2018-2032 (USD MILLION)
  • TABLE 197. AFRICA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 198. AFRICA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 199. AFRICA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 200. AFRICA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 201. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 202. ASEAN NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 203. ASEAN NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. ASEAN NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY JET INJECTOR, 2018-2032 (USD MILLION)
  • TABLE 205. ASEAN NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY MICROARRAY PATCH, 2018-2032 (USD MILLION)
  • TABLE 206. ASEAN NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. ASEAN NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 208. ASEAN NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY BASAL INSULIN, 2018-2032 (USD MILLION)
  • TABLE 209. ASEAN NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY BOLUS INSULIN, 2018-2032 (USD MILLION)
  • TABLE 210. ASEAN NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 211. ASEAN NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY COVID-19 VACCINE, 2018-2032 (USD MILLION)
  • TABLE 212. ASEAN NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY INFLUENZA VACCINE, 2018-2032 (USD MILLION)
  • TABLE 213. ASEAN NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 214. ASEAN NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 215. ASEAN NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. ASEAN NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 217. GCC NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 218. GCC NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. GCC NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY JET INJECTOR, 2018-2032 (USD MILLION)
  • TABLE 220. GCC NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY MICROARRAY PATCH, 2018-2032 (USD MILLION)
  • TABLE 221. GCC NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. GCC NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 223. GCC NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY BASAL INSULIN, 2018-2032 (USD MILLION)
  • TABLE 224. GCC NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY BOLUS INSULIN, 2018-2032 (USD MILLION)
  • TABLE 225. GCC NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 226. GCC NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY COVID-19 VACCINE, 2018-2032 (USD MILLION)
  • TABLE 227. GCC NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY INFLUENZA VACCINE, 2018-2032 (USD MILLION)
  • TABLE 228. GCC NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 229. GCC NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 230. GCC NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 231. GCC NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPEAN UNION NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPEAN UNION NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPEAN UNION NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY JET INJECTOR, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPEAN UNION NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY MICROARRAY PATCH, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPEAN UNION NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPEAN UNION NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPEAN UNION NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY BASAL INSULIN, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPEAN UNION NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY BOLUS INSULIN, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPEAN UNION NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPEAN UNION NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY COVID-19 VACCINE, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPEAN UNION NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY INFLUENZA VACCINE, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPEAN UNION NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPEAN UNION NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPEAN UNION NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPEAN UNION NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 247. BRICS NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 248. BRICS NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 249. BRICS NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY JET INJECTOR, 2018-2032 (USD MILLION)
  • TABLE 250. BRICS NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY MICROARRAY PATCH, 2018-2032 (USD MILLION)
  • TABLE 251. BRICS NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. BRICS NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 253. BRICS NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY BASAL INSULIN, 2018-2032 (USD MILLION)
  • TABLE 254. BRICS NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY BOLUS INSULIN, 2018-2032 (USD MILLION)
  • TABLE 255. BRICS NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 256. BRICS NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY COVID-19 VACCINE, 2018-2032 (USD MILLION)
  • TABLE 257. BRICS NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY INFLUENZA VACCINE, 2018-2032 (USD MILLION)
  • TABLE 258. BRICS NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 259. BRICS NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 260. BRICS NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 261. BRICS NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 262. G7 NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 263. G7 NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 264. G7 NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY JET INJECTOR, 2018-2032 (USD MILLION)
  • TABLE 265. G7 NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY MICROARRAY PATCH, 2018-2032 (USD MILLION)
  • TABLE 266. G7 NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 267. G7 NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 268. G7 NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY BASAL INSULIN, 2018-2032 (USD MILLION)
  • TABLE 269. G7 NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY BOLUS INSULIN, 2018-2032 (USD MILLION)
  • TABLE 270. G7 NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 271. G7 NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY COVID-19 VACCINE, 2018-2032 (USD MILLION)
  • TABLE 272. G7 NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY INFLUENZA VACCINE, 2018-2032 (USD MILLION)
  • TABLE 273. G7 NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 274. G7 NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 275. G7 NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 276. G7 NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 277. NATO NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 278. NATO NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 279. NATO NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY JET INJECTOR, 2018-2032 (USD MILLION)
  • TABLE 280. NATO NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY MICROARRAY PATCH, 2018-2032 (USD MILLION)
  • TABLE 281. NATO NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 282. NATO NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 283. NATO NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY BASAL INSULIN, 2018-2032 (USD MILLION)
  • TABLE 284. NATO NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY BOLUS INSULIN, 2018-2032 (USD MILLION)
  • TABLE 285. NATO NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 286. NATO NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY COVID-19 VACCINE, 2018-2032 (USD MILLION)
  • TABLE 287. NATO NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY INFLUENZA VACCINE, 2018-2032 (USD MILLION)
  • TABLE 288. NATO NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 289. NATO NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 290. NATO NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 291. NATO NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 292. GLOBAL NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 293. UNITED STATES NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 294. UNITED STATES NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 295. UNITED STATES NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY JET INJECTOR, 2018-2032 (USD MILLION)
  • TABLE 296. UNITED STATES NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY MICROARRAY PATCH, 2018-2032 (USD MILLION)
  • TABLE 297. UNITED STATES NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 298. UNITED STATES NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 299. UNITED STATES NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY BASAL INSULIN, 2018-2032 (USD MILLION)
  • TABLE 300. UNITED STATES NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY BOLUS INSULIN, 2018-2032 (USD MILLION)
  • TABLE 301. UNITED STATES NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 302. UNITED STATES NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY COVID-19 VACCINE, 2018-2032 (USD MILLION)
  • TABLE 303. UNITED STATES NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY INFLUENZA VACCINE, 2018-2032 (USD MILLION)
  • TABLE 304. UNITED STATES NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 305. UNITED STATES NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 306. UNITED STATES NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 307. UNITED STATES NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 308. CANADA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 309. CANADA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 310. CANADA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY JET INJECTOR, 2018-2032 (USD MILLION)
  • TABLE 311. CANADA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY MICROARRAY PATCH, 2018-2032 (USD MILLION)
  • TABLE 312. CANADA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 313. CANADA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 314. CANADA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY BASAL INSULIN, 2018-2032 (USD MILLION)
  • TABLE 315. CANADA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY BOLUS INSULIN, 2018-2032 (USD MILLION)
  • TABLE 316. CANADA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 317. CANADA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY COVID-19 VACCINE, 2018-2032 (USD MILLION)
  • TABLE 318. CANADA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY INFLUENZA VACCINE, 2018-2032 (USD MILLION)
  • TABLE 319. CANADA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 320. CANADA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 321. CANADA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 322. CANADA NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 323. MEXICO NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 324. MEXICO NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 325. MEXICO NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY JET INJECTOR, 2018-2032 (USD MILLION)
  • TABLE 326. MEXICO NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY MICROARRAY PATCH, 2018-2032 (USD MILLION)
  • TABLE 327. MEXICO NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 328. MEXICO NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 329. MEXICO NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY BASAL INSULIN, 2018-2032 (USD MILLION)
  • TABLE 330. MEXICO NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY BOLUS INSULIN, 2018-2032 (USD MILLION)
  • TABLE 331. MEXICO NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 332. MEXICO NEEDLE FREE DRUG DELIVERY DEVICE MARKET SIZE, BY COVID-19 VACCINE, 2018-2032 (USD MILLION)
  • TABLE 333. MEXICO NEEDLE FREE DRUG DELIVERY DEVICE